By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Aria Diagnostics said today that it has begun a blinded, multicenter clinical trial that will compare its non-invasive prenatal trisomy 21 screening test with standard screening methods.

The company's test, which is still in development, is based on a sequencing-based method that analyzes cell-free DNA in maternal blood to detect fetal chromosomal abnormalities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.